Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Transplant Proc ; 41(3): 959-61, 2009 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-19376398

RESUMO

The treatment of B-cell non-Hodgkin lymphoma, the most common posttransplant lymphoproliferative disorder, is not well defined. Herein we have reported a case of gastric mucosa-associated lymphoid tissue (MALT) lymphoma with rapid, persistent, and complete remission after conversion of the immunosuppression from cyclosporine (CsA) to sirolimus (SRL). A 42-year-old woman underwent renal transplantation in 1992 with no major abnormalities until 2006 when a gastroscopy performed to investigate dyspeptic symptoms showed a mixed MALT gastric lymphoma (with low- and high-grade components) associated with the presence of Helicobacter pylori infection. Two therapeutic interventions in a 1-week interval were performed: treatment of the H. pylori infection (omeprazole, amoxicillin, and clarithromycin for 14 days) and modification of the immunosuppression by substitution of CsA and azathioprine (AZA) with SRL. Control endoscopy performed 1 month later showed persistence of H. pylori infection and absence of the gastric tumor. New endoscopies performed at 2 and 7 months after therapy confirmed the absence of neoplasia and H. pylori eradication. Currently, the patient has no complaints, displaying a creatinine value of 1.8 mg/dL and a hemoglobin of 9.4 mg/dL using SRL and ibersatan. SRL has been studied extensively as an anticancer drug, acting as a mammalian target for rapamycin (mTOR) inhibitor. Accumulating data support the role of mTOR in lymphomagenesis. In conclusion, our case of gastric MALT lymphoma in a renal transplant patient displayed a complete remission after alteration of the immunosuppressive scheme with the introduction of SRL.


Assuntos
Azatioprina/efeitos adversos , Ciclosporina/efeitos adversos , Mucosa Gástrica/patologia , Imunossupressores/efeitos adversos , Transplante de Rim/imunologia , Linfoma de Zona Marginal Tipo Células B/complicações , Sirolimo/uso terapêutico , Neoplasias Gástricas/complicações , Adulto , Feminino , Infecções por Helicobacter/complicações , Helicobacter pylori , Humanos , Imunossupressores/uso terapêutico , Doadores Vivos , Linfoma de Zona Marginal Tipo Células B/imunologia , Neoplasias Gástricas/imunologia
2.
Transplant Proc ; 37(6): 2775-6, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-16182807

RESUMO

The aim of this study was to compare the progression of renal grafts following treatment of an acute rejection event based on the histological diagnosis of a graft biopsy compared to a presumptive (clinical and laboratory) diagnosis. A historical cohort was used to study 44 patients undergoing a living haploidentical related donor renal transplant, using a similar immunosuppressive treatment: cyclosporine, azathioprine, and prednisone. Acute rejection events were treated with methylprednisolone (250 mg for 3 to 5 days) based on a histological diagnosis (biopsy group = 14) or on a clinical and laboratory diagnosis (presumptive group = 30), which consisted of an elevation over 20% in plasma creatinine in 24 hours and renal ultrasound or scintigraphy findings. The study demonstrated no significant difference in renal function (plasma creatinine) and other outcomes 2 years following transplantation in both groups. The results show that treatment of acute rejection based on a presumptive diagnosis is not a risk factor for unfavorable outcomes following 2 years of renal transplantation monitoring.


Assuntos
Rejeição de Enxerto/tratamento farmacológico , Imunossupressores/uso terapêutico , Transplante de Rim/imunologia , Doença Aguda , Adulto , Biópsia , Estudos de Coortes , Creatinina/sangue , Quimioterapia Combinada , Feminino , Rejeição de Enxerto/mortalidade , Rejeição de Enxerto/patologia , Teste de Histocompatibilidade , Humanos , Rim/diagnóstico por imagem , Rim/patologia , Transplante de Rim/mortalidade , Transplante de Rim/patologia , Masculino , Prednisolona/uso terapêutico , Prednisona/uso terapêutico , Ultrassonografia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA